Circulating miR-143-3p inhibition protects against insulin resistance in Metabolic Syndrome via targeting of the insulin-like growth factor 2 receptor.

@article{Xihua2019CirculatingMI,
  title={Circulating miR-143-3p inhibition protects against insulin resistance in Metabolic Syndrome via targeting of the insulin-like growth factor 2 receptor.},
  author={Lin Xihua and Tang Shengjie and Gui Weiwei and Erik Matro and Tao Tingting and L. C. Lin and Wu Qing Fang and Zhou Jiaqiang and Zheng Fenping and Li Hong},
  journal={Translational research : the journal of laboratory and clinical medicine},
  year={2019},
  volume={205},
  pages={
          33-43
        }
}
Metabolic syndrome (MetS) is characterized by a cluster of metabolic disorders including obesity, dyslipidemia, hyperglycemia, and hypertension. Here, we report that 27 microRNAs were found to be expressed differently in serum and urine samples of MetS patients compared to control subjects on microarray analysis. Further qualitative real time- polymerase chain reaction analyses confirmed that circulating levels of miR-143-3p were significantly elevated in MetS patients compared with controls… CONTINUE READING

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 36 REFERENCES

Circulating MicroRNA-21 is Downregulated in Patients with Metabolic Syndrome.

  • Biomedical and environmental sciences : BES
  • 2016
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Metabolic syndrome and dietary patterns: a systematic review and meta-analysis of observational studies

M Rodrı́guez-Monforte, E Sánchez, F Barrio, B Costa, G. FloresMateo
  • Eur J Nutr
  • 2017
VIEW 1 EXCERPT

MicroRNA Profiling of Exosomes.

  • Methods in molecular biology
  • 2017
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…